Replies to post #284200 on Avid Bioservices Inc (CDMO)

[eb0783]

That is true with the mice

. ......And with humans, as the human results have paralleled the animal results. PS targeting is obviously different from the small molecules and other drug trials back through history. So the animals have moved my needle. Here is why.

Believe who you want but I tend to believe our Beethoven, Dr Thorpe said over ten years ago:

10-24-05: Thorpe, in response to humans vs. animals question: “All animal species have the same regulation. What I haven’t explained is that PS is one in the same molecule in humans, mice, and all higher species. As far as we know, there is no difference in the regulation of these molecules between humans and other species. If you look in culture, it’s precisely the same.”
tinyurl.com/c9bnq

AND:

8-2003 NIAID LASSA Grant: “The phospholipids that they recognize have the same structure and cellular distribution in different mammalian species, simplifying the transition from experimental animals into humans.”
tinyurl.com/5ntcm

ALSO we know that many animals have been CURED of disease and immune to re-infection both in Dr Thorpe’s lab tests and later in Dr Brekken’s lab.

MOREOVER, contrary to what most people believe Bavi may be working EVEN BETTER IN HUMANS, as noted again over ten years ago (think: how much more do we know today?) No wonder we have been sabotaged so many times in our human trials. SOMEONE does not want the world to know what we have [and they have been trying to make us think that our PEARL is worthless. Seems they want us to think they are smarter than Dr. Thorpe].

Peregrine's Bavituximab Shows Promising Anti-Viral Activity and Signs of Prolonged Anti-Viral Effect in Single Dose Monotherapy HCV Trial
TUSTIN, CA, June 7 2006: ……..Joseph Shan, Peregrine's executive director of clinical and regulatory affairs, added, "These first efficacy results in humans are particularly exciting because researchers did not expect to see much anti-viral activity after a single dose of drug, based on our experience in lethal animal disease models such as Lassa fever. Bavituximab demonstrated good anti-viral activity in these studies, but only after administration of multiple doses. Based on the results reported today, the drug's anti-viral potential may be even more promising in humans than the animal models suggest."